Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 6/20 | 0.52 |
| ▸ | HTR1B | P28222 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532963 | 0.92 | NCF1 (0.58) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL8095863 | 0.91 | HTR1D (0.52) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL5529815 | 0.90 | NCF1 (0.51) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL13945359 | 0.90 | HTR1D (0.51) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL13945372 | 0.89 | SMN1; SMN2 (0.52) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL5527438 | 0.89 | HTR1D (0.48) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL5531659 | 0.88 | HTR1D (0.57) | HTR1DHTR1BHTR1ANCF1SSTR5 | |
| SCHEMBL14437441 | 0.88 | NCF1 (0.51) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL13945423 | 0.87 | HTR1D (0.50) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 | |
| SCHEMBL5532964 | 0.87 | HRH3 (0.58) | HTR1DHTR1BHTR1ANCF1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071055-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | HTR1D 1094/4885HTR1B 677/4885HTR1A 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.